IBS. Probiotics have been claimed to be of some benefit in IBS, but the majority of studies have been performed in nonspecific IBS rather than in PI-IBS and a number of issues still remain to be elucidated. 
wide range of prevalence could be explained by a number of factors, including the different clinical settings in which the studies were carried out (i.e. general population vs. referral centers), the different type of infectious agents involved and the criteria used to diagnose IBS. Furthermore, these data must be considered with caution since they are inevitably retrospective in nature. Indeed, the assessment of a cause-effect relationship between the infection and IBS could be biased by the patient's or physician's need to explain symptoms or by poor recall by the patient of the previous infective episode.
The geographical distribution of PI-IBS is remarkably uneven. PI-IBS has been mainly reported in Europe, particularly in the UK (to date, roughly 70% of the studies have come from there). Only recently, two studies, one from China [3] and one from Korea [4] , have reported that PI-IBS also occurs in Eastern countries with a prevalence similar to that found in the West [5] . On the other hand, older data suggest that PI-IBS is almost absent in developing countries, in spite of a high prevalence of gastrointestinal infections in these populations [6, 7] . One study from India reported no association between amoebic infection and IBS [8] . To explain this apparent paradox, Gwee [9] has recently proposed a hygiene hypothesis model. According to this hypothesis, it was speculated that in underdeveloped countries a high exposure to a variety of microorganisms early in life could result in a strong stimulation of the intestinal immune system and the development of broad immune tolerance that enable the intestinal epithelium to respond more efficiently to antigenic challenge, as during an episode of gastroenteritis. The consequence would be that post-infective symptoms resolve more quickly. Conversely, the intestinal immune system remains relatively naive in the more hygienic environment of industrialized countries. Gastrointestinal infections in later life would result in a greater inflammatory disturbance, leading to the persistence of IBS symptoms. Further studies are now needed to confirm this interesting hypothesis.
Etiology, Pathophysiology and Risk Factors
Acute infectious gastroenteritis is a common event in Western countries, occurring on average 1.4 times per year per person. Although the vast majority of subjects recover completely following eviction of the infectious agent, a small but significant proportion of subjects go on to develop long-lasting digestive symptoms [10] . The occurrence of PI-IBS has been confirmed by several prospective studies indicating that long-term IBS symptoms develop in 7-32% of subjects after acute enteritis [11] . One major criticism to these studies is related to the fact that some of them lack a control population, which may lead to an overestimation of the problem. In addition, some studies were carried out with a poor experimental design and limited by a short post-infection follow-up. The fact that only a proportion of patients developed IBS symptoms post-infection suggests the presence of predisposing factors. A number of them have been identified, including virulence of the pathogen, younger age, female sex, long duration of initial illness, and psychological issues (including hypochondriasis and adverse life events) [12] . However, much work is needed to elucidate the exact role of these factors.
The fact that IBS may have an infective origin has created renewed interest and enthusiasm in IBS research. One may even postulate some analogies with the infective (i.e. Helicobacter pylori ) origin of peptic ulcer disease. However, the scenario of PI-IBS is remarkably different. The variety of infective agents involved in the development of IBS symptoms clearly indicates that the etiology is rather variable and therefore the disease is not the consequence of any specific infection. The infectious agents more frequently found to be associated with PI-IBS are Campylobacter , Shigella and Salmonella [10] . Other bacterial agents including viruses and parasites could possibly be involved in the development of PI-IBS; however, supporting data are still lacking. The acute infective episode can be considered only a trigger factor involved in the stimulation of a local (i.e. intestinal) inflammatory response. Patients that go on to develop IBS symptoms post-infection are probably unable to downregulate efficiently this initial inflammatory response. Genetic and psychological factors [11] as well as the use of antibiotics [13] during the acute infective episode have been claimed to be involved in the persistence of the intestinal lowgrade inflammation.
In support of the hypothesis that low-grade intestinal inflammation participated in symptom generation is evidence that other conditions characterized by local lowgrade immune activation such as ulcerative colitis in remission [14] or treated celiac disease [15] are also associated with the development of IBS-like symptoms. Although these studies support the role of inflammatory mechanisms in symptom generation in PI-IBS patients, a clear demonstration of a cause-effect relationship is still awaited. 
Role of Intestinal Microflora
Some studies have provided evidence that intestinal microflora may be altered in patients with IBS. These changes may contribute to the low-grade intestinal inflammatory response described in PI-IBS. However, the role of these changes in the pathophysiology of PI-IBS is still controversial. This is related to our limited knowledge of the intestinal microflora even in healthy human subjects. This has to be ascribed to human microflora complexity, variability and instability and to substantial methodological flaws that hamper an in-depth characterization of indigenous intestinal flora. A more detailed definition of intestinal bacterial populations could be obtained by new molecular techniques such as polymerase chain reaction, quantitative dot-blot, fluorescence in situ hybridization, and DNA microarray [16] . A detailed characterization of intestinal microflora using these newer techniques will most likely require several years of work.
Other potential mechanisms possibly involved in the pathophysiology of PI-IBS include changes in serotonin metabolism [10] and the occurrence of an increased postinfection bile acid malabsorption [17] , but further confirmatory studies are required.
Clinical Management
The discovery that an infective episode may trigger the development of IBS has not substantially changed the clinical management of this subset of patients compared to the classical (non-infective) form of IBS. Indeed, there are no clear preventive measures in PI-IBS. An initial attempt to reduce intestinal inflammation with steroids in PI-IBS has failed to demonstrate any symptomatic improvement [18] . Nonetheless, these apparently disappointing results should be viewed in light of the known side effects of steroids, including those affecting the gastrointestinal tract. Larger trials and eventually testing other anti-inflammatory compounds may provide some better beneficial effect in PI-IBS.
Non-absorbable antibiotics (e.g. rifaximin) have been recently shown to be beneficial in the treatment of nonspecific IBS [19] . Nonetheless, to date there are no available studies assessing a similar approach in PI-IBS. Probiotics have been claimed to be of some benefit in IBS, but the majority of studies have been carried out in non-specific IBS rather than in PI-IBS, conflicting results have also been published [16] and a number of issues still remain to be elucidated. These include the identification of subsets of patients who respond to this type of therapy, better definition of outcome measures, identification of the most effective type of probiotic formulation (e.g. type of strain, multiple vs. single strain, live vs. non-live, spores, yoghurts) and the most effective dose of probiotics. Much work is obviously needed in this interesting field of investigation.
The prognosis of PI-IBS has been suggested to be slightly better to that of non-specific IBS [1] . A 6-year follow-up study in 192 patients showed that symptoms disappeared in 43% of PI-IBS as compared to 31% in nonspecific IBS, and, although this difference did not reach statistical significance, a type B error cannot be excluded [20] .
In conclusion, acute infectious gastroenteritis is an accepted etiological factor in IBS. However, a number of controversial issues regarding its epidemiology and pathophysiology remain to be clarified. For the time being, the clinical management of this subgroup of patients is not different from that of non-specific IBS. Although probiotics hold a great therapeutic promise for patients with PI-IBS, their exact role in the management of these patients needs to be elucidated.
